ADCX-020 enters dose optimization
Adcytherix dosed the first ADCX-020 participant in March 2026. Its first-in-human ADC study includes escalation followed by dose optimization and selected expansion cohorts.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 1 progression — date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links adcytherix.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof.
Potential outcome market
Will ADCX-020 begin dosing in the protocol-defined dose-optimization or expansion stage by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.